TENAX THERAPEUTICS, INC. (TENX) Form 10-Q — Jul 31, 2026
For the six months ended June 30, 2026, Tenax Therapeutics reported a net loss of $33.5 million, or $0.70 per share, compared to a net loss of $21.3 million in the prior year period. Research and development expenses increased 107% to $24.4 million, driven primarily by costs associated with the ongoing Phase 3 LEVEL and LEVEL-2 clinical trials for levosimendan. The company ended the period with cash and cash equivalents of $118.0 million. Management stated that based on current resources and subsequent warrant exercises totaling $8.1 million, funds are sufficient to support operations into the second quarter of 2028.
Key figures
- Eps
- -0.70
- Cash Position
- 117976000
- Runway
- Through the second quarter of 2028
- Shares outstanding
- 37423917
- Subsequent event proceeds
- 8100000
- Research and development expense
- 24389000
- Selling general and administrative expense
- 10968000
Price after filing
Close on the filing date to close N calendar days later (from $14.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.